Analysts expect a launch around 100,000 won a month, about half of Wegovy's starting price. Its 9.02% average weight loss over 40 weeks trails Mounjaro and Wegovy.
Recap by typeshit. Full story at Korea JoongAng Daily.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
Full phase 3 data from EASD and The Lancet: 1,152 adults, three doses over 80 weeks, A1C down about 1.5 points, with diarrhea and nausea the top side effects.
Holly Lofton and Jennifer Manne-Goehler say safety looks similar to other GLP-1s so far, and Lofton reports gray market patients who saw no weight loss at all.
Loading…